Drawing for SAMURAI

USPTO serial 97746884

SAMURAI

Reviewed by CopyMark Law Group

Status 734Notice of Allowance
Filing date
Status date
Registration date
—
Examiner
OJEYEMI, ASHLEY CHRISTINE
Law office
TMO LAW OFFICE 136

What this means

The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.

Status 734: Status 734 means the fifth and typically final extension to file a Statement of Use was granted. You must file an acceptable Statement of Use before this last extension expires or the application will abandon.

Need help with SAMURAI?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,246*

Plus Government fees of $600

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Nancy Sabarra

Nancy Sabarra FROSS ZELNICK LEHRMAN & ZISSU, P.C.151 WEST 42ND ST., 17TH FL.NEW YORK, NY 10036United States

Goods and services

ClassDescriptionStatusFirst use
001Active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research and medical research, namely, for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research useACTIVE—
005Vaccines; vaccine adjuvants; medical, biological, and pharmaceutical preparations for medical use, namely, preparations containing messenger RNA for preventing and treating viruses and respiratory disorders; mRNA-based therapeutics and therapeutic agents for in vivo, ex vivo, or in situ prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; lipid nanoparticles for drug delivery sold as an integral component of drugs; pharmaceutical preparations, namely, messenger RNA and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cellsACTIVE—
042Pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccinesACTIVE—
044Medical services; medical information; providing a website featuring medical informationACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 30, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Sep 30, 2026EX5GSOU EXTENSION 5 GRANTED—
Sep 17, 2026AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Aug 4, 2026EXT5SOU EXTENSION 5 FILED—
Aug 4, 2026EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 22, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
May 21, 2026EX4GSOU EXTENSION 4 GRANTED—
May 21, 2026EXT4SOU EXTENSION 4 FILED—
May 21, 2026EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Dec 17, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Dec 16, 2025EX3GSOU EXTENSION 3 GRANTED—
Dec 16, 2025EXT3SOU EXTENSION 3 FILED—
Dec 16, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 13, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jun 12, 2025EX2GSOU EXTENSION 2 GRANTED—
Jun 12, 2025EXT2SOU EXTENSION 2 FILED—
Jun 12, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 3, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Dec 4, 2024EX1GSOU EXTENSION 1 GRANTED—
Dec 4, 2024EXT1SOU EXTENSION 1 FILED—
Dec 4, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 18, 2024NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Apr 23, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 23, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 3, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 15, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 11, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 11, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 11, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 12, 2023GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 12, 2023GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 12, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 30, 2023DOCKASSIGNED TO EXAMINER—
Apr 17, 2023AMPXPRELIMINARY/VOLUNTARY AMENDMENT - ENTERED—
Apr 14, 2023ALIEASSIGNED TO LIE—
Jan 31, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 19, 2023PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Jan 12, 2023NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance